Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?

Myriad Genetics (MYGN) shares have increased by 23.9% since its last earnings report, outperforming the S&P 500; however, consensus estimates have since trended downward by 5.56%, leading to a Zacks Rank #3 (Hold) and expectations of an in-line return in the coming months. Comparatively, GSK, a peer in the same industry, has gained 9.8% over the past month with positive estimate revisions and a Zacks Rank #2 (Buy).

Analysis

Myriad Genetics (MYGN) has experienced a significant share price increase of 23.9% since its last earnings report, notably outperforming the S&P 500. However, this rally is juxtaposed with a negative trend in analyst estimates, as the consensus estimate has declined by 5.56% over the past month. This divergence contributes to a Zacks Rank #3 (Hold) for MYGN, with expectations for an in-line return in the near term. The company's VGM Scores reflect this mixed picture: a strong 'A' for Growth but a weak 'F' for Momentum, and a 'C' for Value, culminating in an overall 'C' score. In contrast, industry peer GSK has demonstrated more consistent positive signals, with its stock gaining 9.8% over the past month. GSK reported a 1.4% year-over-year revenue increase to $9.46 billion and an EPS of $1.13 for its March-ended quarter, up from $1.09 a year ago. Furthermore, GSK's consensus estimate has seen a +1.9% upward revision in the last 30 days, supporting its Zacks Rank #2 (Buy) and a VGM Score of 'B', with expected earnings per share of $1.12 for the current quarter, representing a 2.8% year-over-year growth.

Key Decisions for Investors

• Given Myriad Genetics' (MYGN) recent share price appreciation juxtaposed with declining analyst estimates and a 'Hold' rating, investors should exercise caution and monitor for potential pullbacks, as the rally may not be supported by underlying estimate trends.
• Investors might consider the more favorable outlook for GSK, which exhibits positive estimate revisions, a 'Buy' rating, and recent earnings growth, as a potentially stronger candidate within the Medical - Biomedical and Genetics industry.
• Closely watch MYGN's next earnings release for catalysts that could either validate the recent share price strength or confirm the concerns raised by downward estimate revisions before making new investment decisions or adjusting existing positions.